scholarly journals Tenofovir Hot-Melt Granulation using Gelucire® to Develop Sustained-Release Vaginal Systems for Weekly Protection against Sexual Transmission of HIV

Pharmaceutics ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 137 ◽  
Author(s):  
Fernando Notario-Pérez ◽  
Raúl Cazorla-Luna ◽  
Araceli Martín-Illana ◽  
Roberto Ruiz-Caro ◽  
Juan Peña ◽  
...  

Hot-melt granulation is a technique used to obtain granules by dispersing a drug in polymers at a high temperature. Tenofovir, an antiretroviral drug with proven activity as a vaginal microbicide, was dispersed in melted Gelucire® (or a mixture of different Gelucire®) to obtain drug-loaded granules. Studies performed on the granules proved that the drug is not altered in the hot-melt granulation process. The granules obtained were included in a matrix formed by the hydrophilic polymers hydroxypropylmethylcellulose and chitosan to obtain vaginal tablets that combine different mechanisms of controlled release: The Gelucire® needs to soften to allow the release of the Tenofovir, and the hydrophilic polymers must form a gel so the drug can diffuse through it. The studies performed with the tablets were swelling behavior, Tenofovir release, and ex vivo mucoadhesion. The tablets containing granules obtained with Tenofovir and Gelucire® 43/01 in a ratio of 1:2 in a matrix formed by hydroxypropylmethylcellulose and chitosan in a ratio of 1.9:1 were selected as the optimal formulation, since they release Tenofovir in a sustained manner over 216h and remain attached to the vaginal mucosa throughout. A weekly administration of these tablets would therefore offer women protection against the sexual transmission of HIV.

Pharmaceutics ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 20 ◽  
Author(s):  
Raúl Cazorla-Luna ◽  
Fernando Notario-Pérez ◽  
Araceli Martín-Illana ◽  
Roberto Ruiz-Caro ◽  
Aitana Tamayo ◽  
...  

Vaginal microbicides have the potential to give women at high risk of contracting HIV the option of self-protection by preventing the sexual transmission of the virus. In this paper, mucoadhesive vaginal tablets based on chitosan, alone and in combination with pectin and locust bean gum, were developed for the sustained release of tenofovir (an antiretroviral drug). The formulations were placed in simulant vaginal fluid (SVF) to swell, and Hg porosity and SEM microscopy were used for the microstructural characterization of the swelling witnesses. The results show that the association of pectin and chitosan generated polyelectrolyte complexes and produced a robust system able to maintain its structure during the swelling process, when small pores are formed. Drug release and bovine vaginal mucoadhesion studies were performed in SVF showing that tenofovir-controlled dissolution profiles and adhesion to the mucosa were conditioned by the swelling processes of the polymer/s in each formulation. Tablets based on chitosan/pectin have the most homogeneous tenofovir dissolution profiles and last up to 96 h, remaining attached to the vaginal mucosa for the same period. These formulations can therefore be considered a good option for the self-protection of women from the sexual transmission of HIV.


2018 ◽  
Vol 4 (2) ◽  
pp. 139-149 ◽  
Author(s):  
Ankita U. Patel ◽  
Dipti V. Caudhari ◽  
Pranav J. Shah ◽  
Shailesh A. Shah

2019 ◽  
Vol 45 (6) ◽  
pp. 959-967 ◽  
Author(s):  
Ran Li ◽  
Tian Yin ◽  
Yu Zhang ◽  
Jingxin Gou ◽  
Haibing He ◽  
...  

2013 ◽  
Vol 102 (12) ◽  
pp. 4330-4336 ◽  
Author(s):  
Sharleen Weatherley ◽  
B.O. MU ◽  
Michael R. Thompson ◽  
Paul J. Sheskey ◽  
Kevin P. O'Donnell

2014 ◽  
Vol 466 (1-2) ◽  
pp. 83-95 ◽  
Author(s):  
Ahmed S Zidan ◽  
Mohamed Ebeed ◽  
Hanaa Elghamry ◽  
Alaia Badawy

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Karen W. Buckheit ◽  
Robert W. Buckheit

Significant advancements in topical microbicide development have occurred since the prevention strategy was first described as a means to inhibit the sexual transmission of HIV-1. The lack of clinical efficacy of the first generation microbicide products has focused development attention on specific antiretroviral agents, and these agents have proven partially successful in human clinical trials. With greater understanding of vaginal and rectal virus infection, replication, and dissemination, better microbicide products and delivery strategies should result in products with enhanced potency. However, a variety of development gaps exist which relate to product dosing, formulation and delivery, and pharmacokinetics and pharmacodynamics which must be better understood in order to prioritize microbicide products for clinical development. In vitro, ex vivo, and in vivo models must be optimized with regard to these development gaps in order to put the right product at the right place, at the right time, and at the right concentration for effective inhibition of virus transmission. As the microbicide field continues to evolve, we must harness the knowledge gained from unsuccessful and successful clinical trials and development programs to continuously enhance our preclinical development algorithms.


2002 ◽  
Vol 28 (1) ◽  
pp. 67-76 ◽  
Author(s):  
Motonori Kidokoro ◽  
Yasuo Haramiishi ◽  
Shinji Sagasaki ◽  
Tsutomu Shimizu ◽  
Yoji Yamamoto

Sign in / Sign up

Export Citation Format

Share Document